Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 4 de 4
Filtrer
Plus de filtres










Base de données
Gamme d'année
1.
Int J Mol Sci ; 24(22)2023 Nov 10.
Article de Anglais | MEDLINE | ID: mdl-38003345

RÉSUMÉ

Phospholipase A2 (PLA2) enzymes influence inflammatory bowel disease in both positive and negative manners depending on the type of PLA2 that is expressed. This study explored the influence of the abundantly expressed Group 1B PLA2 (PLA2G1B) on ulcerative colitis. Wild-type C57BL/6J mice and Pla2g1b-/- mice were treated with dextran sulfate sodium (DSS) for 5 days to induce epithelial injury, followed by another 5 days without DSS for recovery. The Pla2g1b-/- mice displayed significantly less body weight loss, colitis pathology, and disease activity indexes compared to the wild-type mice. The differences in colitis were not due to differences in the colonic lysophospholipid levels, but higher numbers of stem and progenitor cells were found in the intestines of Pla2g1b-/- mice compared to the wild-type mice. The DSS-treated Pla2g1b-/- mice also showed higher expressions of genes that are responsible for epithelial repair and lower expressions of proinflammatory cytokine genes in the colon, as well as reduced inflammatory cytokine levels in the plasma. In vitro experiments revealed the PLA2G1B stimulation of inflammatory cytokine expression by myeloid cells. PLA2G1B inactivation protects against DSS-induced colitis in mice by increasing the intestinal stem cell reservoir for epithelial repair and reducing myeloid cell inflammation in the diseased colon. Thus, PLA2G1B may be a target for colitis management.


Sujet(s)
Rectocolite hémorragique , Colite , Souris , Animaux , Group IB phospholipases A2/métabolisme , Souris de lignée C57BL , Colite/induit chimiquement , Colite/génétique , Colite/métabolisme , Côlon/anatomopathologie , Rectocolite hémorragique/métabolisme , Phospholipases A2/génétique , Phospholipases A2/métabolisme , Cytokines/métabolisme , Sulfate dextran/toxicité , Modèles animaux de maladie humaine , Muqueuse intestinale/métabolisme
2.
Am J Physiol Regul Integr Comp Physiol ; 325(1): R55-R68, 2023 07 01.
Article de Anglais | MEDLINE | ID: mdl-37212552

RÉSUMÉ

This study explored the role of apoE receptor-2 (apoER2), a unique member of the LDL receptor family proteins with a restricted tissue expression profile, in modulating diet-induced obesity and diabetes. Unlike wild-type mice and humans in which chronic feeding of a high-fat Western-type diet leads to obesity and the prediabetic state of hyperinsulinemia before hyperglycemia onset, the Lrp8-/- mice with global apoER2 deficiency displayed lower body weight and adiposity, slower development of hyperinsulinemia, but the accelerated onset of hyperglycemia. Despite their lower adiposity, adipose tissues in Western diet-fed Lrp8-/- mice were more inflamed compared with wild-type mice. Additional experiments revealed that the hyperglycemia observed in Western diet-fed Lrp8-/- mice was due to impaired glucose-induced insulin secretion, ultimately leading to hyperglycemia, adipocyte dysfunction, and inflammation upon chronic feeding of the Western diet. Interestingly, bone marrow-specific apoER2-deficient mice were not defective in insulin secretion, exhibiting increased adiposity and hyperinsulinemia compared with wild-type mice. Analysis of bone marrow-derived macrophages revealed that apoER2 deficiency impeded inflammation resolution with lower secretion of IFN-ß and IL-10 in response to LPS stimulation of IL-4 primed cells. The apoER2-deficient macrophages also showed an increased level of disabled-2 (Dab2) as well as increased cell surface TLR4, suggesting that apoER2 participates in Dab2 regulation of TLR4 signaling. Taken together, these results showed that apoER2 deficiency in macrophages sustains diet-induced tissue inflammation and accelerates obesity and diabetes onset while apoER2 deficiency in other cell types contributes to hyperglycemia and inflammation via defective insulin secretion.


Sujet(s)
Hyperglycémie , Hyperinsulinisme , Insulinorésistance , Animaux , Humains , Souris , Tissu adipeux/métabolisme , Moelle osseuse/métabolisme , Régime alimentaire , Alimentation riche en graisse , Hyperglycémie/métabolisme , Hyperinsulinisme/génétique , Inflammation/métabolisme , Protéine-1 apparentée au récepteur des LDL/métabolisme , Souris de lignée C57BL , Souris knockout , Obésité/étiologie , Obésité/métabolisme , Récepteurs aux lipoprotéines LDL , Récepteur de type Toll-4/métabolisme
3.
J Biol Chem ; 297(3): 101106, 2021 09.
Article de Anglais | MEDLINE | ID: mdl-34425108

RÉSUMÉ

Polymorphisms in the apolipoprotein E (apoE) gene are risk factors for chronic inflammatory diseases including atherosclerosis. The gene product apoE is synthesized in many cell types and has both lipid transport-dependent and lipid transport-independent functions. Previous studies have shown that apoE expression in myeloid cells protects against atherogenesis in hypercholesterolemic ApoE-/- mice. However, the mechanism of this protection is still unclear. Using human APOE gene replacement mice as models, this study showed that apoE2 and apoE4 expressed endogenously in myeloid cells enhanced the inflammatory response via mechanisms independent of plasma lipoprotein transport. The data revealed that apoE2-expressing myeloid cells contained higher intracellular cholesterol levels because of impaired efflux, causing increasing inflammasome activation and myelopoiesis. In contrast, intracellular cholesterol levels were not elevated in apoE4-expressing myeloid cells, and its proinflammatory property was found to be independent of inflammasome signaling and related to enhanced oxidative stress. When ApoE-/- mice were reconstituted with bone marrow from various human APOE gene replacement mice, effective reduction of atherosclerosis was observed with marrow cells obtained from APOE3 but not APOE2 and APOE4 gene replacement mice. Taken together, these results documented that apoE2 and apoE4 expression in myeloid cells promotes inflammation via distinct mechanisms and promotes atherosclerosis in a plasma lipoprotein transport-independent manner.


Sujet(s)
Apolipoprotéine E2/métabolisme , Apolipoprotéine E4/métabolisme , Athérosclérose/génétique , Animaux , Apolipoprotéine E2/génétique , Apolipoprotéine E3/métabolisme , Apolipoprotéine E4/génétique , Apolipoprotéines E/métabolisme , Athérosclérose/métabolisme , Femelle , Humains , Inflammation , Lipoprotéines/métabolisme , Mâle , Souris , Souris de lignée C57BL , Souris transgéniques , Cellules myéloïdes/métabolisme , Transduction du signal
4.
Bioorg Med Chem ; 23(8): 1869-81, 2015 Apr 15.
Article de Anglais | MEDLINE | ID: mdl-25778768

RÉSUMÉ

Current FDA-approved chemotherapeutic antimetabolites elicit severe side effects that warrant their improvement; therefore, we designed compounds with mechanisms of action focusing on inhibiting DNA replication rather than targeting multiple pathways. We previously discovered that 5-(α-substituted-2-nitrobenzyloxy)methyluridine-5'-triphosphates were exquisite DNA synthesis terminators; therefore, we synthesized a library of 35 thymidine analogs and evaluated their activity using an MTT cell viability assay of MCF7 breast cancer cells chosen for their vulnerability to these nucleoside derivatives. Compound 3a, having an α-tert-butyl-2-nitro-4-(phenyl)alkynylbenzyloxy group, showed an IC50 of 9±1µM. The compound is more selective for cancer cells than for fibroblast cells compared with 5-fluorouracil. Treatment of MCF7 cells with 3a elicits the DNA damage response as indicated by phosphorylation of γ-H2A. A primer extension assay of the 5'-triphosphate of 3a revealed that 3aTP is more likely to inhibit DNA polymerase than to lead to termination events upon incorporation into the DNA replication fork.


Sujet(s)
Antimétabolites antinéoplasiques/composition chimique , Antimétabolites antinéoplasiques/pharmacologie , Réplication de l'ADN/effets des médicaments et des substances chimiques , Inhibiteurs de la synthèse d'acide nucléique/composition chimique , Inhibiteurs de la synthèse d'acide nucléique/pharmacologie , Thymidine/analogues et dérivés , Thymidine/pharmacologie , Tumeurs du sein/traitement médicamenteux , Femelle , Humains , Cellules MCF-7
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...